Study and meta-analysis examine exposure to methylphenidate, amphetamines and atomoxetine during pregnancy and neurodevelopmental disorders in offspring.
Since Bill C-64 passed last October, the federal government has been negotiating with the provinces and territories to sign bilateral pharmacare deals. Yet, all we’ve heard from Ontario is that the province can’t commit to sign on until it knows more.
